Sichenzia Ross Ference LLP Represents Inmune Bio, Inc. in a $40.0 Million Registered Direct Offering

Press Release – New York, New York – July 16, 2021 – Sichenzia Ross Ference LLP announced today that it represented Inmune Bio, Inc. (Nasdaq: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, in a registered direct offering of common stock at a purchase price of $22.00 per share with two institutional investor. The gross proceeds from the offering were $40.0 million.
A.G.P./Alliance Global Partners acted as sole placement agent for the offering.
The Sichenzia Ross Ference LLP team was led by partners Marc Ross, Thomas Rose and Barrett DiPaolo.
- Sichenzia Ross Ference LLP Represents EF Hutton in $8.4 Million Simultaneous Registered Direct Offering and Private Placement of Securities of Nemaura Medical, Inc. - February 3, 2023
- Sichenzia Ross Ference LLP Represents Verb Technology Company, Inc. in $7.2 Million Underwritten Public Offering of Common Stock - January 26, 2023
- Sichenzia Ross Ference LLP Represents Jupiter Wellness, Inc. in $4.1 Million Registered Direct Offering and Concurrent Private Placement of Warrants - January 24, 2023